Autonomic innervation of heart is abnormal in diabetes and produces altered cardiovascular parameters. Cerebrolysin is a neurotrophic factor that improves the dendritic tree and synapses in the central nerve system after brain damage. The aim of this study was to evaluate if cerebrolysin can improve the cardiac neuropathy generated in diabetic rats. Male Sprague-Dawley rats two months old were injected with streptozotocin (70 mg/Kg/, ip). Hyperglycemia and altered cardiac rate were confirmed after eight weeks of STZ injection, and cerebrolysin treatment was started in control and diabetic rats for two months (1 ml/kg/day, ip). Body weight, heart rate, heart rate variability, arterial blood pressure, and blood glucose levels were measured. Also heart weight and levels of nitrites, NGF and VEGF were measured in left ventricle homogenates. The results show that body weight was reduced and blood glucose levels were increased significantly in diabetic rats. Cerebrolysin treatment produced no significant changes in body weight either in blood glucose level in control and diabetic rats. Cerebrolysin treatment in diabetic rats shows an improvement in the altered basal cardiac rate (306 ± 6.5 lat/min) compared to diabetic saline group (272 ± 8.9 lat/min: P < 0.05), without changes in control rats. Levels of nitrites, VEGF, and NGF in the left ventricle increased in diabetic cerebrolysin treated rats. In conclusion, the results show that cerebrolysin improves some abnormalities observed in the diabetic cardiac neuropathy in rats and suggest that could be considered an additional treatment to prevent or reduce the cardiac autonomic alterations generated in diabetes.
References
[1]
Vinik, A.I. and Ziegler, D. (2007) Diabetic Cardiovascular Autonomic Neuropathy. Circulation, 115, 387-397.
https://doi.org/10.1161/CIRCULATIONAHA.106.634949
[2]
Kuehl, M. (2012) Cardiovascular Autonomic Neuropathies as Complications of Diabetes Mellitus. Nature Reviews Endocrinology, 8, 405-416.
https://doi.org/10.1038/nrendo.2012.21
[3]
Sanyal, S.N., Wada, T., Yamabe, M., Anai, H., Miyamota, S., Shimada, T. and Ono, K. (2012) Synaptic Degradation of Cardiac Autonomic Nerves in Streptozotocin-Induced Diabetic Rats. Pathophysiology, 19, 209-307.
https://doi.org/10.1016/j.pathophys.2012.08.002
[4]
Forbes, J.M. and Cooper, M.E. (2013) Mechanisms of Diabetic Complications. Phy-siological Reviews, 93, 137-188. https://doi.org/10.1152/physrev.00045.2011
[5]
Giudice, P.L., Careddu, A., Magni, G., et al. (2002) Autonomic Neuropathy in Streptozotocin Diabetic Rats: Effect of Acetyl-L-Carnitine. Diabetes Research and Clinical Practice, 56, 173-180. https://doi.org/10.1016/S0168-8227(01)00375-8
[6]
Li, X., Jiang, Y.-H., Jiang, P., et al. (2015) Analisis of Heart Rate Variability and Car-diac Autonomic Nerve Remodeling in Streptozotocin-Induced Diabetic Rats. Experimental and Clinical Endocrinology and Diabetes, 123, 272-281.
https://doi.org/10.1055/s-0035-1547258
[7]
Hicks, K.K., Seifen, E., Stimers, J. and Kennedy, R.H. (1998) Effects of Streptozotocin-Induced Diabetes on Heart Rate, Blood Pressure, and Cardiac Autonomic Nervous System. Autonomic Neuroscience, 121, 7-15.
[8]
Lin, Y.D., Hsu, K.L., Wu, E.T., et al. (2008) Autonomic Neuropathy Precedes Cardiovascular Dysfunction in Rats with Diabetes. European journal of Clinical Investigation, 38, 607-614. https://doi.org/10.1111/j.1365-2362.2008.01992.x
[9]
Xuan, Y.-L., Wang, Y., Xue, M., et al. (2015). In Rats, the Duration of Diabetes Influences Its Impact on Cardiac Autonomic Innervations and Electrophysiology. Autonomic Neuroscience: Basic and Clinical, 189, 31-36.
https://doi.org/10.1016/j.autneu.2015.01.003
[10]
Felten, S.Y., Peterson, R.G., Shea, P.A., Besch Jr., H.R. and Felten, D.L. (1982) Effects of Streptozotocin Diabetes on the Noradrenergic Innervation of the Rat Heart: A Longitudinal Histofluorescence and Neurochemical Study. Brain Research Bulletin, 8, 593-607. https://doi.org/10.1016/0361-9230(82)90086-7
[11]
Kuncová, J., Sviglerová, J., Tonar, Z. and Slavikova, J. (2005) Heterogeneous Changes in Neuropeptide Y, Norepinephrine and Epinephrine Concentrations in the Heart of Diabetic Rats.
[12]
Lund, D.D., Subieta, A.R., Pardini, B.J. and Chang, K.S. (1992) Alterations in Cardiac Parasympathetic índices in STZ-Induced Diabetic Rats. Diabetes, 41, 160-166.
https://doi.org/10.2337/diab.41.2.160
[13]
Govoni, S., Pascale, A., Amadio, M., et al. (2011) NGF and Heart: Is There a Role in Heart Disease? Pharmacological Research, 63, 266-277.
[14]
Korsching, S. and Thoenen, H. (1983) Nerve Growth Factor in Sympathetic Ganglia and Corresponding Target Organs of the Rat: Correlation with Density of Sympathetic Innervation. Proceedings of the National Academy of Sciences, 80, 3513-3516. https://doi.org/10.1073/pnas.80.11.3513
[15]
Xing, J., Lu, J. and Li, J. (2014) Nerve Growth Factor Decreases in Sympathetic and Sensory Nerves of Rats with Chronic Heart Failure. Neurochemical Research, 39, 1564-1570. https://doi.org/10.1007/s11064-014-1348-5
[16]
Lokhart, S.T., Turrigiano, G.G. and Birren, S.J. (1997) Nerve Growth Factor Modulates Synaptic Transmission between Sympathetic Neurons and Cardiac Myocytes. Journal of Neuroscience, 17, 9573-9582.
[17]
Schmid, H., Forman, L.A., Cao, X., Sherman, P.S. and Stevens, M.J. (1999) Heterogeneous Cardiac Sympathetic Denervation and Decreased Myocardial Nerve Growth Factor in Streptozotocin-Induced Diabetic Rats. Implications for Cardiac Sympathetic Dysinnervation Complicating Diabetes. Diabetes, 48, 603-608.
https://doi.org/10.2337/diabetes.48.3.603
[18]
Vo, P.A. and Tomlinson, D.R. (1999) The Regeneration of Peripheral Noradrenergic Nerves after Chemical Sympathectomy in Diabetic Rats: Effects of Nerve Growth Factor. Experimental Neurology, 157, 127-134.
https://doi.org/10.1006/exnr.1999.7018
[19]
Ieda, M., Kanazawa, H., Ieda, Y., Kimura, K., Matsumura, K., et al. (2006) Nerve Growth Factor Is Critical for Cardiac Sensory Innervation and Rescues Neuropathy in Diabetic Hearts. Circulation, 114, 2351-2363.
https://doi.org/10.1161/CIRCULATIONAHA.106.627588
[20]
Heiss, W.D., Brainin, M., Bornstein, N.M., et al. (2012) Cerebrolysin in Patients with Acute Ischemic Stroke in Asia. Results of a Doublé-Blind, Placebo-Controlled Randomized Trial. Stroke, 43, 630-636.
https://doi.org/10.1161/STROKEAHA.111.628537
[21]
Rockenstein, E., Mante, M., Adame, A., Crews, L., Moessler, H. and Masliah, E. (2007) Effects of Cerebrolysin TM on Neurogenesis in an APP Transgenic Model of Alzheimer’s Disease. Acta Neuropathologica, 113, 265-275.
https://doi.org/10.1007/s00401-006-0166-5
[22]
Solis-Gaspar, C., Vazquez-Roque, R., Gómez-Villalobos, M.J. and Flores, G. (2016) Cerebrolysin Improves Memory and Ameliorates the Neural Atrophy of Spontaneous Hypertension Aged Rat. Synapse, 70, 378-389.
https://doi.org/10.1002/syn.21912
[23]
Rockenstein, E., Desplats, P., Ubhi, K., et al. (2015) Neuropeptide Treatment with Cerebrolysin Improves the Survival of Neural Stem Cells Grafts in an APP Transgenic Model of Alzheimer Disease. Stem Cell Research, 15, 56-67.
[24]
Georgy, G.S., Nassar, N.N., Mansour, H.A. and Abdallah, D.M. (2013) Cerebrolysin Ameliorates Cognitive Deficits in Type III Diabetic Rats. PLoS ONE, e64647.
[25]
Sanchez-Vega, L., Juarez, I., Gómez Villalobos, M.J. and Flores, G. (2015) Cerebrolysin Reverses Hippocampal Neural Atrophy in Mice Models of Diabetes Mellitus Type 1. Synapse, 69, 326-335. https://doi.org/10.1002/syn.21819
[26]
Dong, H.Y., Jiang, X.M., Niu, C.B., Du, L., Feng, J.Y. and Jia, F.Y. (2016) Cerebrolysin Improves Sciatic Nerve Dysfunction in a Mouse Model of Diabetic Peripheral Neuropathy. Neural Regeneration Research, 11, 156-162.
https://doi.org/10.4103/1673-5374.175063
[27]
Ubhi, K., Rockenstein, E., Vazquez Roque, R., Mante, M., et al. (2013) Cerebrolysin Modulates Nerve Growth Factor/Nerve Growth Factor Ratio and Ameliorates the Cholinergic Deficit in a Transgenic Model of Alzheimer’s Disease. Journal of Neuroscience Research, 91, 167-177. https://doi.org/10.1002/jnr.23142
[28]
Feng, M., Whitesall, S., Zhang, Y., Beibel, M., D’Alecy, L. and DiPetrillo, K. (2008) Validation of Volume-Pressure Recording Tail-Cuff Blood Pressure Measurements. American Journal of Hypertension, 12, 1268-1291.
https://doi.org/10.1038/ajh.2008.301
[29]
Gschanes, A., Boado, R., Sametz, W. and Windisch, M. (2000) The Drug Cerebrolysin and Its Peptide Fraction E021 Increases the Abundance of the Blood-Brain Barrier GLUT1 Glucose Transporter in Brain of Young and Old Rats. The Histochemical Journal, 32, 71-77. https://doi.org/10.1023/A:1004003008683
[30]
Pieper, G.M. (1998) Review of Alterations in Endothelial Nitric Oxide Production in Diabetes. Protective Role of Arginine on Endothelial Dysfunction. Hypertension, 31, 1047-1060. https://doi.org/10.1161/01.HYP.31.5.1047
[31]
Cellek, S., Foxwell, N. and Moncada, S. (2003) Two Phases of Nitrergic Neuropathy in Streptozotocin-Induced Diabetic Rats. Diabetes, 52, 2353-2362.
https://doi.org/10.2337/diabetes.52.9.2353
[32]
Stockklauser-Farber, K., Ballhausen, T. and Rosen, P. (2000) Influences of Diabetes on Cardiac Nitric Oxide Synthase Expression and Activity. Biochimica et Biophysica Acta, 1535, 10-20.
[33]
Soliman, H., Craig, G.P., Nagareddy, P., et al. (2008) Role of Inducible Nitric Oxide Synthase in Induction of RhoA Expression in Hearts from Diabetic Rats. Cardiovascular Research, 79, 322-330. https://doi.org/10.1093/cvr/cvn095
[34]
Nagareddy, P.R., Xia, Z., McNeill, J.H. and MacLeod, K.M. (2005) Increased Expression of iNOS Is Associated with Endothelial Dysfunction and Impaired Pressure Responsiveness in Streptozotocin-Induced Diabetes. American Journal of Physiology. Heart and Circulatory Physiology, 289, H2144-H2152.
https://doi.org/10.1152/ajpheart.00591.2005
[35]
Khanna, S., Singh, G.U. and Khullar, M. (2014) Nitric Oxide Synthase and Diabetic Cardiomyopathy. Nitric Oxide, 43, 29-34.
[36]
Han, B., Baliga, R., Huang, H., Giannone, P.J. and Bauer, J.A. (2009) Decreased Cardiac Expression of Vascular Endothelial Growth Factor and Redox Imbalance in Murine Diabetic Cardiomyopathy. American Journal of Physiology. Heart and Circulatory Physiology, 297, H829-H835. https://doi.org/10.1152/ajpheart.00222.2009
[37]
Chou, E., Suzuma, I., Way, J.K., et al. (2002) Decreased Cardiac Expression of Vascular Endothelial Growth Factor and Its Receptors in Insulin-Resistant and Diabetic States. A Possible Explanation for Impaired Collateral Formation in Cardiac Tissue. Circulation, 105, 373-379. https://doi.org/10.1161/hc0302.102143
[38]
Yoon, Y., Uchida, S., Masuo, O., et al. (2005) Progressive Attenuation of Myocardial Vascular Endothelial Growth Factor Expression Is a Seminal Event in Diabetic Cardiomyopathy. Restoration of Microvascular Homeostasis and Recovery of Cardiac Function in Diabetic Cardiomyopathy after Replenishment of Local Vascular Endothelial Growth Factor. Circulation, 111, 2073-2085.
https://doi.org/10.1161/01.CIR.0000162472.52990.36
[39]
Jesmin, S., Zaedi, S., Shimojo, N., et al. (2007) Endothelin Antagonism Normalizes VEGF Signaling and Cardiac Function in STZ-Induced Diabetic Rat Hearts. American Journal of Physiology—Endocrinology and Metabolism, 292, E1030-E1040.
https://doi.org/10.1152/ajpendo.00517.2006
[40]
Patockova, J., Krsiak, M., Marhol, P. and Tumova, E. (2003) Cerebrolysin Inhibits Lipid Peroxidation Induced by Insulin Hypoglycemia in the Brain and Heart of Mice. Physiological Research, 52, 455-460.
